Subgroups | Appropriate EAMT group (n = 41) | Inappropriate EAMT group (n = 38) | ||
---|---|---|---|---|
Enlargement (n = 22) | Change (n = 9) | De-escalation (n = 7) | ||
Bacteriologic documentation, n | 28/41 | 18/22 | 9/9 | 7/7 |
NI location | ||||
 VAP | 22 | 11 | 2 | 4 |
 Bacteraemia | 3 | 7 | 3 | 2 |
 CRI | 2 | 5 | 3 | 0 |
 CRB | 1 | 1 | 0 | 1 |
 UI | 0 | 1 | 1 | 0 |
Isolates (n) | ||||
 Acinetobacter B | 14 | 6 | 0 | 0 |
 Klebsiella pneumonia | 6 | 4 | 0 | 0 |
 Pseudomonas spp. | 5 | 5 | 3 | 5 |
 Enterobacter | 2 | 4 | 1 | 0 |
 E. coli | 0 | 1 | 0 | 0 |
 Staphylococcus | 0 | 4 | 1 | 0 |
 Enterococcus | 0 | 3 | 1 | 0 |
 Stenotrophomonas M | 0 | 3 | 2 | 0 |
 Burkholderiacepacia | 1 | 0 | 0 | 0 |
 Streptocoque spp. | 0 | 0 | 0 | 2 |
 Candida species | 0 | 7 | 1 | 0 |
Antimicrobial adjustment | Imipenem/colistin | Imipenem/colistin/Glycopeptid (n = 8) | Other betalactam (for resistance to impenem)  + tygecycline, aminoglycoside or quinolone (n = 6) | Piperacilline (n = 2) |
Imipenem/colistin/antifungal (n = 7) | Glycopeptide ± aminoside (n = 2) | Ceftazidime (n = 3) | ||
Imipenem/colistin/Tygecycline/aminglyosides (n = 3) | Antifungal (n = 1) | Cefotaxime (n = 2) |